Brief: FDA Approves Joenja (Leniolisib) As First Treatment For APDS In Children Aged 4-11 Years
11/09/2026 17:08
BRIEF-FDA Approves Joenja (Leniolisib) As First Treatment For APDS In Children Aged 4-11 Years Sept 11 (Reuters) - FDA:
FDA APPROVES FIRST TREATMENT FOR CHILDREN AGED 4-11 YEARS WITH APDS, A RARE GENETIC DISORDER OF IMMUNE SYSTEM
FDA : APPROVES JOENJA (LENIOLISIB) AS FIRST TREATMENT FOR APDS IN CHILDREN AGED 4-11 YEARS
FDA: JOENJA APPROVED AT WEIGHT-BASED DOSE OF 40, 50, OR 70 MG ORALLY TWICE DAILY FOR CHILDREN 4-11 YEARS
Further company coverage: PHAR.AS
((Reuters.Briefs@thomsonreuters.com;;))